Surfactant medication for acute respiratory distress syndrome

Simon V Baudouin

Department of Anaesthesia and Intensive Care, University of Newcastle and Royal Victoria Infirmary, Newcastle upon Tyne, UK

Introductory article

Aerosolized surfactant in adults with sepsis-induced respiratory distress syndrome

A Anzueto, RP Baughman, KK Guntupalli, JG Weg, HP Wiedemann, AA Raventos, F Lemaire, W Long, for the Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group

Background. Patients with acute respiratory distress syndrome (ARDS) have a deficiency of surfactant. Surfactant replacement improves physiologic function in such patients, and preliminary data suggest that it may improve survival. **Methods.** We conducted a prospective, multicenter, double-blind, randomized, placebo-controlled trial involving 725 patients with sepsis-induced ARDS. Patients were stratified according to the risk of death at base line (indicated by their score on the Acute Physiologic and Chronic Health Evaluation [APACHE III] index) and randomly assigned to receive either continuously administered synthetic surfactant (13.5 mg of dipalmitoylphosphatidylcholine per millilitre; 364 patients) or placebo (0.45 percent saline; 361 patients) in aerosolized form for up to five days. **Results.** The demographic and physiologic characteristics of the two treatment groups were similar at base line. The mean ($\pm$ SD) age was 50 ± 17 years in the surfactant group and 53 ± 18 years in the placebo group, and the mean APACHE III scores at randomization were 70.4 ± 25 and 70.5 ± 25 , respectively. Hemodynamic measures, measures of oxygenation, duration of mechanical ventilation, and length of stay in the intensive care unit did not differ significantly in the two groups. Survival at 30 days was 60 percent for both groups. Survival was similar in the groups when analyzed according to APACHE III score, cause of death, time of onset and severity of ARDS, presence or absence of documented sepsis, underlying disease, whether or not there was a do-not-resuscitate order, and medical center. Increased secretions were significantly more frequent in the surfactant group; the rates of other complications were similar in the two groups. **Conclusions.** The continuous administration of aerosolized synthetic surfactant to patients with sepsis induced ARDS had no significant effect on 30 day survival, length of stay in the intensive care unit, duration of mechanical ventilation, or physiologic function. (N Engl J Med 1996; 334:1417–21)

The acute respiratory distress syndrome (ARDS) is characterised by a severe impairment in pulmonary gas exchange that occurs in critically ill patients following a variety of local and systemic insults. Although the list of potential causes is long, three conditions – severe multiple trauma, large volume emergency blood transfusions, and the severe sepsis syndrome/septic shock – are responsible for many of the cases seen in general intensive care units.¹ Estimates of incidence have varied widely, particularly due to previous differences in definition, and values between 3.5 and 75 cases per year per 100 000 population have been frequently quoted. These figures translate into 10–15 cases of ARDS each year being seen in an average size district general hospital in the United Kingdom. This order of magnitude estimate immediately demonstrates the difficulty of conducting any effective research into the condition within a single treatment centre.

Although relatively uncommon, ARDS has attracted considerable research effort. This reflects the high mortality associated with the condition, which is often in excess of 50%, and the fact that patients with ARDS and the related multi-organ dysfunction syndrome occupy a disproportionate number of bed days in intensive care units and consume a considerable amount of their resources.² Successful treatments for ARDS would therefore have important economic as well as individual patient benefits.

One approach that appeared promising in experimental trials and early pilot studies in man was the use of artificial surfactant replacement therapy. Natural surfactant is a complex mixture of surfactant proteins (SP-A, B and C), neutral lipids, and phospholipids released by type II alveolar cells. Surfactant has a vital role in the preservation of normal lung mechanics. It both reduces absolute surface tension at the alveolus

and allows surface tension to vary continuously with the size of the alveolus. These actions maintain lung fluid balance and reduce the work of breathing. Surfactant also has additional anti-inflammatory actions with some evidence for anti-cytokine and neutrophil stabilising roles in the lung.³

The trial by Anzueto and co-workers⁴ was a logical extension of studies in both neonates with the respiratory distress syndrome (RDS) and patients with ARDS. Artificial surfactants are now routinely used in neonatal RDS with clinical trials showing significant reductions in mortality. In ARDS there is evidence for both a reduction in the quantity and function of surfactant. Type II alveolar cells may be damaged, reducing the synthesis and release of surfactant, the high concentrations of plasma proteins entering the alveolus may inhibit surfactant function, and protease and reactive oxygen species may also inhibit function. In theory therefore the addition of artificial surfactant in ARDS should improve outcome by reinflating collapsed lung units and reducing pulmonary shunt. Barotrauma should also be decreased by the postulated improvement in the distribution of ventilation.

Disappointingly, 30 day survival in the surfactant study was identical in both groups. The most obvious explanation is that the hypothesis tested was incorrect and surfactant function is irrelevant to outcome in ARDS. However, the study can be criticised on a number of technical issues. The artificial surfactant used, Exosurf, is protein free and does not contain surfactant proteins. These may be important in promoting surfactant function and preventing breakdown in the lung. Nebulisation was used as the method of delivery to the lung. This has been shown to result in less than 5% deposition of surfactant in the alveolus and to result in deposition predominantly in ventilated lung units only. In addition, the method of ventilation used and the level of PEEP significantly alter deposition. Finally, the patients were predominantly medical rather than postoperative with Gram positive organisms being the most common pathogens. The results of the study may not be applicable to different patient groups and, in particular, patients with trauma related ARDS may have a different response to surfactant.

Researchers in the field of ARDS (and the pharmaceutical companies) have developed a tradition of well conducted, large, multicentre, randomised, controlled clinical trials. The introductory article on surfactant treatment is a recent example of a long line of such studies in ARDS. Initial investigators focused on the mechanisms producing low pressure pulmonary oedema due to the often dramatic presentation of the syndrome with severe hypoxaemia and diffuse bilateral infiltrates on plain chest radiographs. This research continues to yield new insights into pathophysiology with recent evidence that the resolution of oedema involves an active cellular pumping process. However, within the last decade there has been a change in the direction of research with the discovery of a major acute inflammatory component to the lung injury that occurs in ARDS.⁵⁻⁷ This has coincided with the explosive growth in the basic science of acute inflammation driven by the range of new techniques available in the field of cellular and molecular biology. This work has generated a number of new hypotheses about the origins of acute lung injury and suggested novel approaches to treatment.

Single centre trials (unless they are major tertiary referral units) are unlikely to test new treatments for ARDS successfully because of the relatively low in-

cidence of the condition. The need for well conducted, large scale, double blind clinical trials has not been neglected by the critical care community. This was highlighted in a recent editorial aptly entitled "An anecdote is an anecdote is an anecdote . . . but a clinical trial is data".⁸ One of the main concerns of the editorial was the potential problems with the uncritical introduction and subsequent standard adoption of expensive and unproved technology; the case in point was adult extracorporeal membrane oxygenation (ECMO) in the intensive care environment. More recent reports of the use of haemofiltration in septic shock show that the grey area that exists between generation of hypotheses and established treatment in intensive care has not disappeared.

Clinical trials in ARDS

Investigators in the field of ARDS have taken two basic approaches to treatment trials (figs 1 and 2). The first group have concentrated primarily on the lung alone while the second have viewed the lung injury as part of a systemic process and have targeted treatment in a more global manner.

The studies were identified by Medline accompanied by hand searching review articles and major critical care journals (table 1). Some studies on patients with severe sepsis (septic shock) are also included because of the large overlap between this syndrome and ARDS. It is likely that any treatment that would reduce mortality in septic shock would also reduce the incidence of ARDS and other organ dysfunction.

Mechanical treatments aimed at improving lung function

The intensivist treating the lung in ARDS is faced with a basic dilemma summarised by the question of lung rest versus lung recruitment.⁹ In the early stages of ARDS the process of alveolar flooding is not uniform. Functionally the lung in patients with ARDS consists

Figure 1 Summary of treatment strategies in randomised controlled trials in ARDS targeted at the lung.

Figure 2 Summary of treatment strategies targeted systemically in randomised controlled trials of ARDS.

Table 1 Summary of published randomised, controlled clinical trials in ARDS							
Author	Treatment	Year published	Total no. of patients	Control numbers	Treatment numbers	Mortality (% treatment/control)	Outcome
Zapol ¹²	EMCO	1979	90	48	42	88/90	NS
Pepe ¹⁴	PEEP	1984	92	48	44	NA	NS
Bernard ²³	Steroids	1987	99	49	50	60/63	NS
Yu ²⁹	Ketoconazole	1993	54	28	26	15/39	S (for treatment)
Jepsen ²⁸	N-acetylcysteine	1992	66	34	32	53/50	NS
Luce ²⁴	Steroids	1988	75	37	38	58/54	NS
Mitchell ³⁷	Fluid restriction	1992	101	49	52	35/47	NS
Bone ³⁰	PGE	1989	100	50	50	60/48	NS
Carlon ¹⁶	Jet ventilation	1983	309	157	152	62/62	NS
Bone ²⁵	Steroids	1987	304	152	152	22/52	S (for placebo)
Anzueto ⁴	Surfactant	1996	725	361	364	40/40	NS
Hayes ³⁵	Increased Do ₂	1994	100	50	50	54/34	S (for placebo)
Gattinoni ³⁶	Increased Do ₂	1995	762	252	2 groups of 253 and 257	48/49/52	NS
Morris ¹³	ECMO	1994	40	19	21	58/67	NS

NS = not significant; S = significant; NA = not applicable; ECMO = extracorporeal membrane oxygenation; PEEP = positive end expiratory pressure; PGE = prostaglandin E.

of a distinct population of lung units, a reduced number of normal gas exchanging units, and an increased number of abnormal, flooded and collapsed units. The collapsed units are responsible for the large physiological shunt that is one of the characteristics of the illness. In addition there is a third population of partially collapsed and potentially recruitable lung units. Studies of lung mechanics and computerised tomographic scanning indicate that these partially collapsed units are in a dynamic state and can open and close during the respiratory cycle.¹⁰ If these units can initially be expanded and then stabilised gas exchange should improve and ultimate survival could increase. It was recognised at an early stage in ARDS research that the application of positive end expiratory pressure (PEEP) would often improve gas exchange and the serial examination of lung compliance curves suggested that the recruitment of collapsed lung units was a major mechanism for the improvement with PEEP.

There was also early recognition of the adverse effects of positive airway pressures, whether in the form of PEEP or produced by ventilation with high mean airway pressures. Cardiac output is reduced and barotrauma, in the form of recurrent pneumothoraces, occurs. Recently it has been recognised that even modest levels of positive airway pressure can cause lung damage, at least experimentally, and there is growing concern that the levels of PEEP and airway pressure that are so effective in improving gas exchange in the short term may worsen the acute lung injury process.¹¹ These views have prompted the development of low pressure/low volume ventilation strategies. The two conflicting views of lung management – recruitment versus rest – have been partially tested in controlled trials.

The philosophy behind adult extracorporeal membrane oxygenation (ECMO) trials has been to reduce ventilatory support by using an external gas exchanging system. Outcome should be improved by reducing barotrauma and “allowing the lungs to heal”. This hypothesis was tested by the National Heart, Lung and Blood Institute in the late 1970s using arteriovenous bypass.¹² Mortality in both control and treatment groups was extremely high (88% and 90%, respectively) with no significant improvement in outcome in the treatment group. A number of problems were apparent in the study including an atypical population with a high incidence of bacterial and viral pneumonia and significant co-

agulation problems associated with the prolonged bypass technique. Following the study enthusiasm for this approach fell in North America but a number of European groups continued with a modified technique of venovenous ECMO. Uncontrolled studies reported a significant improvement in outcome with survival in the region of 40%. This prompted a further controlled trial in North America of the modified ECMO technique.¹³ The study had a number of interesting features including the use of pressure controlled inverse ratio ventilation in the control group and the inclusion of strict protocol driven treatment in both groups. Overall survival in both groups was similar to the uncontrolled European studies and significantly better than that in the original North American ECMO study. The very high mortality of the original ECMO study can probably be explained by the unusual case mix of the population and the complications of prolonged arteriovenous bypass. The second study emphasised the importance of using current controlled groups rather than historical ones when evaluating new intensive care technology.

The alternative approach of recruiting collapsed lung units has also been investigated in randomised controlled trials. In one study PEEP was applied to patients at high risk of developing ARDS but did not affect the incidence of subsequent lung injury or related complications.¹⁴ Modern microprocessor technology has led to the development of large numbers of mechanical ventilators and ventilator modes, many of which have been used in ARDS.¹⁵ Some of these have been shown to be effective in the short term improvement of gas exchange but very few randomised controlled trials have studied longer term outcome in terms of survival. This is at least partly due to the less stringent requirements that new ventilator technologies have to meet in terms of proven efficacy compared with new drug treatments.

High frequency jet ventilation has been compared with volume cycled ventilation in a randomised controlled study in adult patients with acute lung injury.¹⁶ No difference in outcome was found and treatment failures and crossovers occurred in both directions. The physiology of jet ventilation is complex and not completely understood and “improved” jet ventilators have been developed since the original studies. In addition, the success of other types of high frequency ventilation in the neonatal and paediatric population make the re-evaluation of the technology in adults likely.

Also on the horizon are the results of a multicentre study examining the ventilatory approach of “permissive hypercapnia”. This method deliberately limits airway pressure (and therefore minute volume) to avoid barotrauma. As a consequence, alveolar ventilation is often inadequate to maintain a normal Paco_2 which is allowed to rise above normal. A retrospective report suggested that the approach could be effective in ARDS¹⁷ but the results of the clinical trial have not as yet been published.

Pharmacological approaches to improving lung function

A number of studies have examined the effect of surfactant therapy in adult ARDS.^{4,18} In adults with ARDS two relatively small initial studies reported significant benefits in terms of outcome but a recent large ($n=725$) multicentre trial found no difference in outcome compared with placebo.⁴ The overall mortality of 40% in both groups was within expected limits for ARDS and there was also no significant difference in other primary end points including duration of mechanical ventilation, length of stay in the intensive care unit, or physiological function.

Another agent with local actions on the lung and a unique delivery system is nitric oxide (NO).¹⁹ It is a powerful gaseous vasodilator with additional anti-inflammatory properties and it can be delivered to the lung during mechanical ventilation. The selective vasodilation of ventilated lung units can result in improved pulmonary gas exchange in acute lung injury and the agent is currently the subject of randomised clinical trials in ARDS.

Local versus systemic treatment in ARDS

The above treatment strategies are linked by the idea that improving respiratory function and/or pulmonary gas exchange will improve outcome in ARDS. The fact that they have been unsuccessful challenges the view that agents and treatments that only act on the lung will be successful in treating ARDS. There is a large body of evidence that ARDS is often only one part of the syndrome of multi-organ dysfunction.²⁰ Frank multi-organ failure occurs in approximately 70% of patients with ARDS and more subtle signs of multi-organ dysfunction occur in almost all cases.

Following an initial inciting stimulus a state of systemic inflammation occurs which is known as the systemic inflammatory response syndrome (SIRS).²¹ The immunological basis for the syndrome remains unclear but there is evidence of widespread acute inflammation in a variety of organs including the lung. This is confirmed by the presence in the air spaces of large numbers of neutrophils and other soluble inflammatory mediators including cytokines, proteases, and oxygen free radicals.³ Some inflammatory mediators may be locally produced in the lung but there is also evidence of early systemic inflammation with high circulating levels of acute phase proteins, cytokines, complement factors, and soluble adhesion molecules. The inflammatory response also precedes clinical evidence of acute lung injury with reports of both systemic and local (lung) inflammatory mediator production occurring before and, to some degree, predicting the onset of organ damage and failure.²² Treatment in ARDS that is only focused on the lung may therefore not result in improvement in overall outcome.

Systemic anti-inflammatory agents in ARDS

CORTICOSTEROIDS

The use of steroid treatment in a wide variety of inflammatory disorders has led a number of investigators to study their actions in ARDS. Three randomised placebo controlled studies have been performed, all with similar negative outcomes.^{23–25} High dose methyl prednisolone was given to 50 of 99 patients with established ARDS from a variety of causes.²³ Treatment was started at a relatively early stage in the illness but, despite this, there was no difference in 45 day mortality (60% in the methyl prednisolone group, 35% in the placebo limb), reversal of ARDS, or infectious complications.

Sepsis and septic shock are major risk factors for the development of ARDS and other investigators have examined the possibility of preventing ARDS by the early use of steroid therapy. This approach is supported by a large body of experimental evidence indicating that steroid therapy given before a systemic insult may reduce or even prevent the development of organ injury. One study examined the effect of high dose methyl prednisolone on the subsequent development of ARDS in patients with septic shock.²⁴ A total of 87 patients entered the study of whom 13 in the treatment group and 14 in the placebo group subsequently developed ARDS. Overall mortality was also similar with 22 deaths in the treatment arm and 20 in the placebo group.

A larger multicentre trial of the early use of methyl prednisolone in the prevention of ARDS in patients with septic shock enrolled 304 patients over a three year period.²⁵ No difference in the subsequent development of ARDS was found (methyl prednisolone 32%, placebo 25%) but 14 day mortality in patients who developed ARDS was significantly higher (52%) than in the placebo group (22%). Despite these clearly negative results, research into the possible use of high dose steroids in ARDS continues. One major area of interest is the use of steroids in patients with the so-called fibroproliferative stage of ARDS.²⁶ Serial studies of inflammatory markers in lung lavage fluid as well as lung biopsy tissue have shown that the process of lung injury in ARDS can evolve from an initial inflammatory and cellular stage to a more chronic organising and fibrosing process. In many respects this is similar to the situation that occurs in more chronic interstitial lung disease. A subgroup of patients has been reported who remain ventilator dependent following the acute stage of their illness. A number of these patients have evidence of a continuing inflammatory process within their lungs as demonstrated by persistent elevation of neutrophils and cytokines in bronchoalveolar lavage fluid. Lung biopsy specimens showed a fibrosing process occurring in the lungs with no evidence of infection. High dose steroid therapy was reported to result in considerable improvements in gas exchange but, as yet, there are no data from a placebo controlled trial.

ANTIOXIDANT THERAPY

A large number of inflammatory mediators are released during the early stages of ARDS. One group of mediators which has attracted research interest are the oxygen free radicals. These are highly reactive species with unpaired electrons produced by both white blood cells and the endothelium. They cause oxidant related damage to a variety of cell structures including lipid peroxidation of cell membranes. Naturally occurring antioxidant systems exist to prevent this damage but these can be overwhelmed in times of high oxidant stress. The po-

tential importance of lung oxidant damage was shown in a study which found very low circulating levels of antioxidants in a group of high risk patients who later developed ARDS.²⁷ N-acetylcysteine has an important antioxidant and free radical scavenger action and a number of uncontrolled studies have suggested that it might be effective in ARDS. However, a placebo controlled randomised study on 66 patients with ARDS found no difference in terms of overall outcome, lung compliance, or gas exchange.²⁸

THE ARACHADONIC ACID CASCADE

Metabolites of the arachadonic acid cascade have both pro and anti-inflammatory properties and a number of pharmacological agents have been used in ARDS that modify these pathways.

Ketoconazole is best known as an antifungal agent but it is also a potent inhibitor of thromboxane A₂ production. Thromboxane A₂ is both a pulmonary vasoconstrictor and has pro-aggregation effects on platelets and white cells. An uncontrolled study reported that it might prevent the development of ARDS in high risk patients and this hypothesis was then tested in a randomised placebo controlled trial in 54 surgical patients admitted to a single intensive care unit.²⁹ The study showed a reduction in ARDS (64% in the placebo group, 15% in the ketoconazole group) as well as a significant reduction in overall mortality. Although the study was relatively small and based on a single centre, the magnitude of the changes are impressive and the results of larger multicentre studies are awaited with great interest.

The potential anti-inflammatory benefits of arachadonic acid metabolites have also been investigated. Prostaglandin E₁ (PGE₁) can prevent platelet aggregation, reduce neutrophil mediated inflammatory responses, and cause systemic pulmonary vasodilation. One hundred patients with established ARDS were randomised to receive either PGE₁ or placebo.³⁰ Mortality in both groups was similar with a trend to higher mortality in the treatment group.

The neutrophil is a potential therapeutic target in acute lung injury and there is currently great interest in the way in which the neutrophil interacts with the vascular endothelium.³¹ A series of adhesive steps are involved where binding occurs between complementary surface molecules on the neutrophil and endothelium resulting in neutrophil rolling, arrest, and transmigration into the tissues. One important group of adhesion molecules are the integrins and the integrin CD11b/CD18 plays a role in establishing firm adhesion between neutrophils and the endothelium.³² Liposomal PGE₁ has significant anti-adhesive actions, probably as a result of binding and downregulating integrin molecules. The compound improved oxygenation and decreased ventilator dependency in a small multicentre study of patients with early ARDS and a trend towards decreased mortality was also reported.³³ Large multicentre studies both in Europe and North America are currently being undertaken.

Manipulating the circulation in ARDS

Shock, both septic and haemorrhagic, often precedes ARDS. Investigations into the circulatory changes associated with ARDS appeared to demonstrate that the normal relationship between oxygen supply and consumption was altered.³⁴ The normal response to a gradual reduction in the oxygen supply to the tissues is the

preservation of tissue oxygen consumption until a point is reached where circulatory and cellular regulatory mechanisms are overwhelmed. Further reduction in oxygen supply causes progressive reductions in cellular oxygen consumption and lactic acidosis. Patients with ARDS and sepsis were reported to have an altered oxygen supply/consumption relationship which lacked the critical inflection point found in normal subjects. Oxygen consumption then appeared to be dependent on oxygen supply over a very wide range of values. It was proposed that multi-organ failure was a result of the reduction in intracellular oxygen consumption and could be prevented by increasing tissue oxygen delivery above the range normally found in health. This led to a number of studies examining the effect of supranormal oxygen delivery on outcome in critically ill patients.

Two large and well conducted randomised control studies have been undertaken.^{35,36} The smaller of the two (n=100)³⁵ found an increased mortality in the treatment group who received dobutamine to augment oxygen delivery whilst the second multicentre study (n=762)³⁶ found no difference in outcome between treatment and placebo groups. Both trials enrolled heterogeneous groups of critically ill patients but the multicentre study found no significant difference in any organ system failure including acute lung injury. There was also no difference in outcome in the group classified as having acute respiratory failure. It is unlikely that treatments aimed at achieving supranormal tissue oxygen delivery would improve outcome in ARDS and could even be harmful.

Although there is an enormous interest in the inflammatory aspects of ARDS, it should not be forgotten that the initial abnormalities of gas exchange are caused by alveolar flooding due to epithelial and endothelial leakage. An approach that reduces the formation of pulmonary oedema or increases its resolution could be beneficial. There have been a number of uncontrolled studies on the benefits of reducing the extravascular water content of the lung in patients with ARDS. These have usually involved some degree of fluid restriction coupled with the early use of vasoconstrictors to support the circulation. One randomised prospective study investigated the effect of reducing extravascular lung water in 91 patients with pulmonary oedema who had undergone pulmonary artery catheterisation.³⁷ In the subgroup with ARDS, where extravascular lung water was reduced by a protocol of fluid restriction and early use of inotropes, both the number of days on a ventilator and the number of days in the intensive care unit were reduced. Mortality was not significantly altered but the study was not sufficiently powerful to detect moderate differences in mortality and the trend was in favour of the group in whom extravascular water was reduced.

Conclusions

These controlled trials of treatment in ARDS are important despite the mostly negative results. The studies are very difficult to perform and the ability of the coordinators of the most recent studies to recruit more than 700 patients into their trials is proof of the fact that intensive care medicine has established itself in the last decade as a mature discipline throughout Europe and North America. The studies also allow intensivists to begin to practise evidence based medicine and to avoid treatments that are of no use or may even be harmful.

It cannot, however, be denied that the trial results have been disappointing and require careful examination

LEARNING POINTS

- * A significant number of large, placebo controlled, randomised, controlled clinical trials of treatment have been performed in ARDS.
- * These can be broadly divided into those that attempted to improve lung function/gas exchange and those that were targeted at systemic inflammatory or circulatory changes.
- * The majority of interventions, including a recent large multicentre study on surfactant replacement, have been ineffective or even harmful.
- * To date no large scale multicentre, randomised, controlled clinical trial has been able to demonstrate a definite benefit of a specific treatment in ARDS.

of the underlying assumptions made in the design of the studies. The results of the recent surfactant trial in adult ARDS highlights some of these problems. In the neonate single organ failure – that is, the lung – is the rule and the primary role of surfactant depletion in causing lung injury is well understood. This has led to a number of treatments which have improved outcome in neonatal respiratory distress syndrome including surfactant replacement, high frequency ventilation, and ECMO. There are major differences in both the cause of acute lung injury and associated problems in the acute respiratory distress syndrome. Lung injury is rarely the sole organ system showing dysfunction and the outcome from ARDS is significantly related to the number and degree of failing organ systems. The majority of patients die *with* rather than *from* ARDS and the cause of death in most of these is multi-organ failure. It is perhaps not surprising that interventions that are solely targeted at the lung in ARDS have not improved outcome.

The failure of systemic treatments in ARDS cannot be so simply explained but the complexity and redundancy of the inflammatory process make the potential benefits of targeting single inflammatory mediators questionable. Additional difficulties arise because of the dual nature of the inflammatory response with its potential to both resist infection and also to cause uncontrollable organ damage. Some multicentre studies of patients with sepsis, treated with monoclonal antibodies to cytokines, have reported increased mortality in the treatment groups. These results provide a harsh reminder that not all inflammation is harmful.

The negative results in the reviewed studies could easily produce a cynical response to the prospect of further research in ARDS treatment and the recent surfactant trial seems to confirm this view. However, the success of surfactant treatment in neonatal respiratory distress only serves to emphasise the fact that improved outcomes in ARDS will only come from a combination of scientific research into basic pathophysiology and continuing interest in well conducted clinical trials.

1 Beale R, Grover ER, Smithies M, Bihari D. Acute respiratory distress syndrome ("ARDS"): no more than severe acute lung injury? *BMJ* 1993;**307**:1335–9.

2 Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. *JAMA* 1994; **271**:226–33.

3 Nicholas TE, Doyle IR, Berston AD. Surfactant replacement therapy in ARDS: white knight or noise in the system? *Thorax* 1997;**52**:195–7.

4 Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, *et al*. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. *N Engl J Med* 1996;**334**: 1417–21.

5 Repine JE. Scientific perspectives on the adult respiratory distress syndrome. *Lancet* 1992;**339**:466–72.

6 Cipolle MD, Pasquale MD, Cerra FB. Secondary organ dysfunction. From clinical perspectives to molecular mediators. *Crit Care Clin* 1993;**9**:261–98.

7 Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. *Intensive Care Med* 1995;**21**:277–85.

8 Donahoe M, Rogers RM. An anecdote is an anecdote is an anecdote . . . but a clinical trial is data. *Am J Respir Crit Care Med* 1994;**149**: 293–4.

9 Stoller JK, Kacmarek RM. Ventilatory strategies in the management of the adult respiratory distress syndrome. *Clin Chest Med* 1990;**11**: 755–72.

10 Marini JJ. Lung mechanics in the adult respiratory distress syndrome: recent conceptual advances and implications for management. *Clin Chest Med* 1990;**11**:673–90.

11 Baudouin SV. Overview of the effects of mechanical ventilation on the pulmonary circulation. In: Peacock AJ, ed. *Pulmonary circulation. A handbook for clinicians*. London: Chapman and Hall, 1996.

12 Zapol WM, Snider MT, Hill JD, Fallat RJ, Bartlett RH, Edmunds LH. Extracorporeal membrane oxygenation in severe acute respiratory failure: a randomized prospective study. *JAMA* 1979;**242**:2193–6.

13 Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF, Weaver LK. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO₂ removal for adult respiratory distress syndrome. *Am J Respir Crit Care Med* 1994;**149**:295–305.

14 Pepe PE, Hudson LD, Carrico CJ. Early application of positive end-expiratory pressure in patients at risk for the adult respiratory-distress syndrome. *N Engl J Med* 1984;**311**:281–6.

15 Sasson CSH, Mahutte CK, Light RW. Ventilator modes: old and new. *Crit Care Clin* 1990;**6**:605–34.

16 Carlon GC, Howland WS, Ray C, Miodownik S, Griffin JP, Groeger JS. High-frequency jet ventilation. A prospective randomized evaluation. *Chest* 1983;**84**:551–9.

17 Hickling KG, Henderson SJ, Jackson R. Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. *Intensive Care Med* 1990; **16**:372–7.

18 Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D, *et al*. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. *JAMA* 1994;**272**:1433–8.

19 Rossaint R, Pappert D, Falke K. Nitric oxide and the pulmonary circulation. *Curr Opin Crit Care* 1996;**2**:29–34.

20 Moore FA, Moore EE. Evolving concepts in the pathogenesis of post injury multiple organ failure. *Surg Clin North Am* 1995;**75**:257–77.

21 Ahmed NA, Christou NV, Meakins JL. The systemic inflammatory response syndrome and the critically ill surgical patient. *Curr Opin Crit Care* 1995;**1**:290–305.

22 Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, *et al*. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. *Lancet* 1993;**341**:643–7.

23 Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, *et al*. High-dose corticosteroids in patients with the adult respiratory distress syndrome. *N Engl J Med* 1987;**317**:1565–70.

24 Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. *Am Rev Respir Dis* 1988;**138**:62–8.

25 Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. *Chest* 1987;**92**:1032–6.

26 Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, El Torkey M, Leeper KV. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. *Chest* 1991;**100**:943–52.

27 Leff JA, Parsons PE, Day CE, Taniguchi N, Jochum M, Fritz H, *et al*. Serum antioxidants as predictors of adult respiratory distress syndrome in patients with sepsis. *Lancet* 1993;**341**:777–80.

28 Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. *Crit Care Med* 1992;**20**:918–23.

29 Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. *Crit Care Med* 1993;**21**: 1635–42.

30 Bone RC, Slotman G, Maunder R, Silverman H, Hyers TM, Kerstein MD, *et al*. Randomized double-blind, multi-centre study of prosta-

glandin E₁ in patients with the adult respiratory distress syndrome. Prostaglandin E₁ Study Group. *Chest* 1989;**96**:114-9.

31 Stewart M, Thiel M, Hogg N. Leukocyte integrins. *Curr Opin Cell Biol* 1995;**7**:690-6.

32 Wortel CH, Doerschuk CM. Neutrophils and neutrophil-endothelial cell adhesion in adult respiratory distress syndrome. *New Horizons* 1993;**1**:631-7.

33 Abraham E, Park YC, Covington P, Conrad SA, Schwartz M. Liposomal prostaglandin E₁ in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. *Crit Care Med* 1996;**24**:10-15.

34 Pallares LC, Evans TW. Oxygen transport in the critically ill. *Respir Med* 1992;**86**:289-95.

35 Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med* 1994;**330**:1717-22.

36 Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, *et al*. A trial of goal-orientated hemodynamic therapy in critically ill patients. *N Engl J Med* 1995;**333**:1025-32.

37 Mitchell JP, Schuller D, Calandrino FS, Schuster DP. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. *Am Rev Respir Dis* 1992;**145**:990-8.